NDA 019758 · Heritage Life
Clozaril
Clozapine · Oral · Atypical Antipsychotic
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jun 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Sep 26, 1989
Approved uses
2
Original approval plus efficacy supplements
Registered trials
127
19 Phase 3, 11 recruiting
FAERS reports
126,443
119,771 serious, 22,748 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Severe Neutropenia CLOZARIL has caused severe neutropenia which is associated with an increased risk of serious and potentially fatal infections. Prior to initiating CLOZARIL treatment, obtain baseline ANC(s). CLOZARIL initiation is not recommended in patients with a baseline ANC less than 1500/μL (less than 1000/μL for those with Benign Ethnic Neutropenia (also known as Duffy-null associated neutrophil count)). See recommendations for dosage modifications based on ANC levels during CLOZARIL treatment [see Dosage and Administration ( 2.3 , 2.4 )] . Consider a hematology consultation before initiating CLOZARIL or during CLOZARIL treatment [see Warnings and Precautions ( 5.1 )] ....
What it is approved for
From the label in effect Jun 6, 2025.
CLOZARIL is an atypical antipsychotic indicated for: • Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to standard antipsychotic treatment ( 1.1 ) • Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior. ( 1.2 ) 1.1 Treatment-Resistant Schizophrenia CLOZARIL is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see Warnings and Precautions ( 5.1 , 5.4 )]. The effectiveness of CLOZARIL in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing CLOZARIL and chlorpromazine in patients who had failed other antipsychotics [see Clinical Studies ( 14.1 )] . 1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder CLOZARIL is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death. The effectiveness of CLOZARIL in reducing the risk of recurrent suicidal...
Mechanism: The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D 2 ) and the serotonin type 2A (5-HT 2A ) receptors. CLOZARIL also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2002 Supplement 47 · Efficacy · priority review LetterReviewLabel
- Sep 26, 1989 Original approval · Type 1 - New Molecular Entity · priority review OtherOther Important Information from FDA
4 products under this application
- CLOZARIL · CLOZAPINE 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
- CLOZARIL · CLOZAPINE 100MG · TABLET, ORAL · Prescription · TE AB
- CLOZARIL · CLOZAPINE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
- CLOZARIL · CLOZAPINE 25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clozapine" as an intervention, any sponsor and status, largest first.
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)Pivotal-lookingCompleted
Shanghai Mental Health CenterAcademic, hospital or other
NCT03510325 · 762 participants · Start Feb 12, 2019 · Primary completion Sep 27, 2023
Drug: Phase 1: Olanzapine; Phase 1: Risperidone and 7 more · For: Schizophrenia
Sites: Beijing, China; Wuhan, China; Nanjing, China · 7 sites in all
- CLOZAPINE Response in Biotype-1Pivotal-lookingRecruiting
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT04580134 · 524 participants (planned) · Start Mar 1, 2022 · Primary completion Apr 30, 2027
Drug: clozapine; risperidone · For: Schizophrenia; Schizoaffective Disorder; Bipolar 1 Disorder
Sites: Hartford, Connecticut; Athens, Georgia; Chicago, Illinois · 5 sites in all
- Optimization of Treatment and Management of Schizophrenia in EuropePivotal-lookingCompleted
Rene KahnAcademic, hospital or other
NCT01248195 · 479 participants · Start May 2011 · Primary completion Apr 2016
Drug: Amisulpride open label; 6-week amisulpride double blind treatment and 2 more · For: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder
Sites: Melbourne, Australia; Innsbruck, Austria; Leuven, Belgium · 26 sites in all
- The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.Pivotal-lookingRecruiting
Dr. Inge WinterAcademic, hospital or other
NCT05958875 · 418 participants (planned) · Start Aug 1, 2024 · Primary completion Jun 30, 2028
Drug: Clozapine; Second-line Antipsychotics (treatment as usual) · For: Schizophrenia and Related Disorders; Early Treatment-Resistance
Sites: Innsbruck, Austria; Augsburg, Germany; Bielefeld, Germany · 13 sites in all
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Sequential Treatment Approaches for Treatment-Resistant SchizophreniaPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT07918222 · 300 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 1, 2030
Drug: [Phase 1] Clozapine; [Phase 1] Aripiprazole and 1 more · For: Treatment-resistant Schizophrenia
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia18,972
- hospitalisation12,562
- death12,371
- schizophrenia4,755
- white blood cell count increased4,541
- white blood cell count decreased4,532
- neutrophil count increased4,203
- drug ineffective4,034
- malaise3,900
- off label use3,854
- treatment noncompliance3,399
- pneumonia3,316
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,706 |
| 2005 | 1,588 |
| 2006 | 2,443 |
| 2007 | 924 |
| 2008 | 932 |
| 2009 | 1,994 |
| 2010 | 2,874 |
| 2011 | 5,628 |
| 2012 | 4,175 |
| 2013 | 3,012 |
| 2014 | 3,388 |
| 2015 | 4,170 |
| 2016 | 4,537 |
| 2017 | 7,274 |
| 2018 | 6,822 |
| 2019 | 7,450 |
| 2020 | 8,080 |
| 2021 | 7,359 |
| 2022 | 13,918 |
| 2023 | 13,134 |
| 2024 | 11,704 |
| 2025 | 8,282 |
| 2026 | 5,039 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Clozaril (Clozapine)
2024 spending
$11.8M
Beneficiaries
589
8,193 claims
Per beneficiary
$20,091
$13.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $16,137,287 |
| 2021 | $14,076,535 |
| 2022 | $13,300,890 |
| 2023 | $12,675,376 |
| 2024 | $11,833,375 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. · Lancet 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T, McCutcheon RA, Vano L, et al. · Lancet Psychiatry 2020 · Comparative Study, Network Meta-Analysis
- Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis.
Yellepeddi VK, Race JA, McFarland MM, et al. · Int J Clin Pharmacol Ther 2024 · Systematic Review, Meta-Analysis
- Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates.
Diniz E, Fonseca L, Rocha D, et al. · Braz J Psychiatry 2023 · Meta-Analysis, Systematic Review
- A systematic review of clozapine-associated inflammation and related monitoring.
Leung JG, Zhang L, Markota M, et al. · Pharmacotherapy 2023 · Systematic Review
- Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Kane J, Honigfeld G, Singer J, et al. · Arch Gen Psychiatry 1988 · Clinical Trial, Comparative Study
Sponsor: Heritage Life
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.